hand eczema

hand ec·ze·ma

eczema that predominantly and persistently affects the hands; of multiple causation, including allergic, industrial, irritant, dyshidrotic, bacterial, and atopic mechanisms; distinguished from chapped hands by the presenc of vesiculation or spongiosis.

hand eczema

A nonspecific term for any dermopathy that primarily affects the hands.
Mentioned in ?
References in periodicals archive ?
Talat Masood Akbar's presentation was on Frequency of allergic dermatitis in patients of hand eczema.
HANDY HELP The ALPHA trial, co-ordinated by Leeds University, is recruiting people with hand eczema which hasn't responded to prescription steroid creams.
Fruit and vegetable juices such as orange, lemon, onion, potato and tomato can irritate hand eczema
5%), asteatotic eczema in 4 cases (2%), 2 (1%) cases each of seborrheic dermatitis, nummular eczema in 2 cases (1%), hand eczema in 3 cases (1.
Also elevate your suspicion in patients with therapyresistant hand eczema, adult- or childhood-onset atopic dermatitis without childhood eczema, as well as in cases of severe or widespread dermatitis prior to initiating a systemic immunosuppressant.
Also elevate your suspicion in patients with therapy-resistant hand eczema, adult- or childhood-onset atopic dermatitis without childhood eczema, as well as in cases of severe or widespread dermatitis prior to initiating a systemic immunosuppressant.
After three months of ingesting six 500 mg capsules per day, my hand eczema was gone.
Results Most of the patients in this series presented with hand eczema (40%), which was followed by dermatitis localized to site of contact with metal (20%) and facial dermatitis including eyelid dermatitis (15%).
The company reported a solid cash position, including short-term investments, of CHF 149 million as of June 30, 2012, which was further strengthened by an additional CHF 224 million following the recently announced completion of the transaction with Stiefel, a GSK company, related to Basilea's hand eczema drug Toctino (alitretinoin).
The company also reported a solid cash position, including short-term investments, of CHF149m as of 30 June 2012, which was further strengthened by an additional CHF224m following the recently announced completion of the transaction with Stiefel, a GSK company, related to Basilea's hand eczema drug Toctino (alitretinoin).
The medicine is the only prescription drug specifically approved for severe chronic hand eczema in adults whose disease does not respond to potent topical steroids.
Basilea said that it is possible to also apply for approval for alitretinoin in 2012 as it expects to report topline data for the alitretinoin US Phase III trial for chronic refractory hand eczema in the first quarter of this year.